Cost considerations in determining the affordability of adjuvant trastuzumab in breast cancer

W Szpak, R P Abratt

Authors' affiliations

W Szpak, Rainbow Oncology' Amanzimtoti, South Africa

R P Abratt, Head of Clinical Governance, Independent Clinical Oncology Network; Emeritus Professor of Radiation Oncology, University of Cape Town, South Africa

Full Text

PDF (92KB)


Trastuzumab; Breast cancer; Affordability

Cite this article

South African Medical Journal 2017;107(1):10-11. DOI:10.7196/SAMJ.2017.v107i1.12172

Article History

Date submitted: 2016-12-21
Date published: 2016-12-21

Article Views

Abstract views: 157
Full text views: 227

Comments on this article

*Read our policy for posting comments here